The effect of BACE1 inhibition in the amyloid plaque-associated axonal dystrophies by Ferreira Rodrigues, Eva Sofia
Dissertation zur Erlangung des Doktorgrades  
der Fakultät für Chemie und Pharmazie  
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
The effect of BACE1 inhibition in the amyloid plaque-
associated axonal dystrophies 
 
 
 
 
 
 
Eva Sofia Ferreira Rodrigues 
 
aus 
 
Leiria, Portugal 
 
 
 
 
 
 
 
 
 
 
 
 
 
2016 
 
 
 
 
 
 
 
Erklärung 
 
Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. 
November 2011 von Herrn Prof. Dr. Jochen Herms betreut und von Herrn PD 
Dr. Stylianos Michalakis von der Fakultät für Chemie und Pharmazie 
vertreten. 
 
 
 
Eidesstattliche Versicherung 
 
Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet.  
 
 
 
 
München, 16.09.2016 
 
 
 
 
 
 
 
 
................................................................. 
                                                                          (Eva Sofia Ferreira Rodrigues) 
 
 
 
 
 
 
 
 
Dissertation eingereicht am 16.09.2016 
 
1. Gutachter: PD Dr. Stylianos Michalakis 
2. Gutacher: Prof. Dr. Jochen Herms  
 
Mündliche Prüfung am 25.10.2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to my grandmother, 
 
Avó Maria 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgments  
 
 
Firstly, I would like to express my gratitude to my supervisor Prof. Dr. Jochen Herms 
for conceiving me this project and for continuous support of my PhD study and 
related research.  
Secondly, I would like to thank Dr. Lidia Blazquez-Llorca for her keen interest for the 
project, innovative suggestions, for her help doing the EM, motivation and immense 
knowledge.  
I would like to thank my fellow labmate Sonja Blumenstock for teaching me the two-
photon imaging technique. I would also like to thank Severin Filser, Finn Peters, 
Carmelo Sgobio and Petar Marinković for the help and technical advises. I would like 
to thank Hazal Salihoglu for working together in solving technical problems and for 
her motivation.  
An enormous thank to my labmate and friend Elena Montagna for all the fun and 
adventures we had in the last three years; for the stimulating discussions and for her 
patient during my moments of frustration.   
 
To my family, that I feel profoundly indebted, and my Portuguese friends that were 
always in contact from Portugal, my sincere and special thank is going to be in 
Portuguese:  Em primeiro lugar quero agradecer aos meus pais e ao meu irmão, do 
fundo do meu coração, pela incansável motivação, por ouvirem os meus desabafos, 
por me apoiarem e darem força. Obrigada por todos os bons momentos que 
partilhámos nas minhas férias. Obrigada mãe pela tua paciência, amor e companhia.  
À minha prima Marina obrigada pelo apoio e motivação. À Eduarda, obrigada pelas 
horas que passámos na treta e as risadas que nos animaram os maus dias. À minha 
amiga Ana Padilha, um especial obrigada pela motivação, apoio e companhia via 
skype.  Ao meu querido amigo Simões, que infelizmente já não está entre nós e à Ti 
Lurdes, também quero agradecer pela força e conselhos que me deram. Aos meus 
queridos amigos “Os Mais Fixes” Ânia, Jaque, Luísa, Joana, Marilu, Filipa, Marta, 
Vera, Fábio e Maria por todas as conversas, apoio e bons momentos que passámos. 
À Telma por todas as viagens que fez até aqui, por me ouvir e por todos os 
fantásticos momentos que passamos juntas. Aos meus amigos portugueses que 
conheci em Munique, Tiago Soares, Tony, Liandro, Inês e Tiago Marcelos, obrigada 
pelas jantaradas, saídas e risadas que tornaram dias aborrecidos em dias divertidos. 
	
Then, I will personally thank everyone, which were always somehow present during 
my PhD here in Munich.		
	 1	
Table	of	contents	
List	of	abbreviations	.................................................................................................................	3	
Summary	..................................................................................................................................	4	
INTRODUCTION	........................................................................................................................	5	
1.	 Alzheimer’s	disease	......................................................................................................	5	
1.1.	 Definition	and	history	...........................................................................................	5	
1.2.	 Pathological	hallmarks	..........................................................................................	6	
1.3.	 Epidemiology	........................................................................................................	8	
1.4.	 Genetics	of	Alzheimer’s	disease	...........................................................................	9	
1.5.	 Mouse	models	of	Alzheimer’s	disease	...............................................................	11	
2.	 Amyloid	pathology	......................................................................................................	13	
2.1.	 Amyloid	Precursor	Protein	.................................................................................	13	
	 Structure	and	function	....................................................................................	13	2.1.1
	 Proteolytic	processing	of	APP	and	Aβ	generation	..........................................	14	2.1.2
	 BACE-1	............................................................................................................	15	2.1.3
2.2.	 Amyloid	peptide	.................................................................................................	17	
2.2.1.	 Aggregation	and	accumulation	of	Aβ	.........................................................	17	
2.2.2.	 The	amyloid	cascade	hypothesis	................................................................	19	
2.3.	 Amyloid	plaques	.................................................................................................	21	
2.3.1.	 Dense-core	and	diffuse	plaques	.................................................................	21	
2.3.2.	 Plaque-associated	axonal	dystrophies	........................................................	23	
3.	 Investigating	plaque-associated	presynaptic	dystrophies	..........................................	25	
3.1.	 The	APPSwe/PSEN1dE9	mouse	model	...............................................................	25	
3.2.	 In	vivo	two-photon	imaging	in	mouse	models	of	AD	..........................................	26	
3.3.	 BACE1	inhibitor	–	a	prime	drug	target	for	AD	....................................................	27	
MATERIAL	AND	METHODS	.....................................................................................................	29	
1.	 Genotyping	.................................................................................................................	29	
2.	 Animals	and	Housing	..................................................................................................	30	
3.	 BACE1	Inhibitor	...........................................................................................................	31	
4.	 Two-Photon	in	vivo	imaging	.......................................................................................	31	
5.	 Immunohistochemistry	and	confocal	imaging	...........................................................	32	
6.	 Aβ	quantification	........................................................................................................	33	
7.	 Electron	microscopy	preparation	and	TEM	imaging	..................................................	34	
8.	 Images,	data	processing	and	statistics	.......................................................................	35	
RESULTS	..................................................................................................................................	36	
	 2	
1.	 Reduction	of	Aβ40	and	Aβ42	levels	by	pharmacological	inhibition	of	BACE1	............	36	
2.	 Inhibition	of	BACE1	induces	hair	depigmentation	......................................................	36	
3.	 BACE1	inhibitor	rescues	the	dynamics	of	axonal	dystrophies	....................................	37	
4.	 BACE1	inhibitor	affects	Aβ	plaque	growth	in	cerebral	cortex	....................................	42	
5.	 Inhibition	of	BACE1	attenuates	the	progression	of	axonal	pathology	depending	on	
the	distance	between	Aβ	fibrils	and	axons	.........................................................................	44	
6.	 Ultrastructural	analysis	of	the	intracellular	accumulation	of	organelles	at	amyloid	
plaques	...............................................................................................................................	48	
DISCUSSION	............................................................................................................................	52	
REFERENCES	...........................................................................................................................	58	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 3	
List of abbreviations 
 
 
Aβ  Amyloid β 
AD  Alzheimer’s disease 
AIDC  APP intracellular domain 
APP  Amyloid Precursor Protein 
ApoE  Apolipoprotein E 
APLP  APP-like protein 
BACE1 β-site APP enzyme 1  
BACE2 β-site APP enzyme 2 
BBB  Blood-brain barrier 
βCTF  C-terminal fragment, named C99 
CNS  Central nervous system 
CSF  Cerebrospinal fluid 
eGFP  Enhanced Green Fluorescent Protein 
ER  Endoplasmic reticulum 
FAD  Familial AD 
LAMP1 Lysosomal-associated membrane protein 1 
NFTs  Neurofibrillary tangles 
PB  Sodium phosphate buffer 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction     
PSEN  Presenilin 
SORL1 Sortilin-related receptor 1 
TGN  Trans-Golgi-network 
TREM2 Triggering receptor expressed on myeloid cells 2  
3D  Three dimension 
 
 
 
 
 
 
 
 
 
 
	 4	
Summary  
 
Alzheimer’s disease (AD) is the most common age-related neurodegenerative 
disease pathologically characterized by the presence of neurofibrillary tangles 
(NFTs), neuropil threads and dystrophic axons. Dystrophic axons are associated 
with extracellular depositions of amyloid β (Aβ), known as plaques and present as 
swollen tortuous neurites, with variable morphology and composition depending on 
the pathological stage of AD. Among other mechanisms, the presence of dystrophic 
axons has been observed to contribute to the synaptic alterations in AD.  
Moreover, axonal dystrophies are enriched with amyloid precursor protein (APP) and 
β-site APP enzyme 1 (BACE1). The accumulation of these two proteins results from 
localized defects in axonal lysosome transport and maturation leading to an increase 
of BACE1 levels and processing of APP. Thus, over the time, it leads to an Aβ 
overproduction, exacerbating the formation of dystrophic axons and the progression 
of amyloid pathology in AD. 
For these reasons, BACE1, as the enzyme that initiates the amyloidogenic pathway, 
is a promising therapeutic target for reducing Aβ levels. We performed chronic two-
photon in vivo imaging and immunohistochemistry to analyze the effect of 
pharmacological BACE1 inhibition on the amyloid pathology in the cerebral cortex of 
AD transgenic mice. We observed that after BACE1 inhibitor treatment, the plaque 
growth rate decreased notably and majority of the analyzed dystrophic axons were 
recovered. Furthermore, during the 3 months of BACE1 inhibitor treatment, the 
formation of new dystrophies was not observed. 
Based on our results, BACE1 inhibition might be a therapeutic opportunity for limiting 
the amyloidogenic processing of APP at dystrophic axons and the development of 
axonal pathology in close proximity to amyloid plaques contributing to the disease 
progression. 
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INTRODUCTION 
 
 
1. Alzheimer’s disease 
 
 
1.1.  Definition and history 
 
 
AD is the most common age-related neurodegenerative disease. While there is no 
cure for the disease, it is one of the most devastating diagnoses given to the patients 
and their families. 
Clinically, AD is characterized by memory deficits and progressive loss of cognitive 
abilities. Memory decline initially manifests as a loss of episodic memory, which is 
considered to be a selective defect of declarative memory. At first, the dysfunction in 
episodic memory impedes the recollection of recent events including 
autobiographical activities. Gradually, memory is lost along with cognitive abilities 
such as orientation, language, problem solving, calculation and visuospatial 
perception. In late stages, AD patients are mentally and physically dependent on 
others for care (Jucker et al. 2006).  
Alois Alzheimer (Figure 1) identified the first case of AD in the early part of the 20th 
century. In 1901, Auguste Deter (Figure 1), a 51-year old woman who had developed 
memory deficits, progressive loss of cognitive abilities and psychiatric symptoms was 
examined by Alzheimer. Due to her middle age and the progression of her 
behavioral symptoms, Alzheimer conducted several investigations to study Deter’s 
case. Five years later, when she died, Alzheimer performed an autopsy that revealed 
the histological alterations in the cerebral cortex. The analysis of her behavioral 
symptoms together with the isolation of pathological alterations, gave the name to 
this condition known as Alzheimer’s disease (M. B. Graeber and Mehraein 1999; 
Manuel B. Graeber 1999; García-Marín, García-López, and Freire 2007; Jucker et al. 
2006).  
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Figure 1: Identification of Alzheimer’s disease. Alois Alzheimer (left) and his first diagnosed patient 
with AD, Augusta Deter (right). Public domain photos. 
 
 
1.2.  Pathological hallmarks 
 
Pathologically, AD is characterized by three abnormalities of the brain, which were 
described by Alzheimer macroscopically and microscopically.  
Macroscopically, the brain is atrophied, with widened sulci, reduced weight and 
enlarged ventricles. These alterations do not occur uniformly throughout the brain, 
but affect notably specific regions. The hippocampi, the neocortex, particularly the 
temporal and frontal lobes, are especially vulnerable.   
Microscopically, the major neuropathological hallmark of AD is the extracellular 
deposition of amyloid plaques formed by aggregates of Aβ. These extracellular 
deposits of Aβ are surrounded by swollen axons and dendrites (Figure 2). Moreover, 
the remaining affected neurons have cytoskeletal abnormalities, which consist of 
intracellular accumulation of NFTs (Figure 3). These tangles contain paired helical 
filaments formed by hyperphosphorylated tau (a microtubule-associated protein).  
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Figure 2: Stages of classical senile plaque formation in the cortex. (A-C) Cajal's histological 
preparations with the reduced silver nitrate methods and (D-F) original drawings to represent his 
discoveries. Figures adapted from (García-Marín, García-López, and Freire 2007). 
 
As AD progresses, the reduction in brain volume, especially in the entorhinal cortex 
and hippocampus, results from the prominent synapse loss and neuronal cell death. 
These alterations in the entorhinal cortex and hippocampus are the base of the 
selective defect in declarative memory, which is the first symptom of AD (Manuel B. 
Graeber 1999; M. B. Graeber and Mehraein 1999; Jucker et al. 2006).  
 
 
Figure 3: Drawings of neurofibrillary tangles stained with silver impregnation method performed by 
Sala (1913). Figure adapted from (Javier DeFelipe 2009). 
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1.3.  Epidemiology 
 
AD is the dominant cause of dementia worldwide during aging processes. By the age 
of 85, between 25-40% of the people have developed AD, and on a global scale 
there are an estimated 46 million people living with dementia (Alzheimer’s 
Association 2010; Alzheimer’s Association 2012; Alzheimer’s Association 2015; 
Wimo, Winblad, and Jönsson 2010; “World Alzheimer Report 2015: The Global 
Impact of Dementia | Alzheimer’s Disease International” 2016). Therefore, as the 
human population ages it is predicted that over 100 million individuals will have AD in 
2050. 
Currently, there is no treatment for curing AD, only treatments to relief both cognitive 
and behavioral symptoms temporally. As the number of AD patients is growing, 
researchers are investing to find new effective treatments to slow down, prevent or 
even stop the progression of the AD. This turns in a global economic impact in order 
to improve the quality of life for patients and their families.  
AD patients have a life expectation between 7-10 years on average, although some 
of them can live for 20 years from the time of diagnosis to death. Moreover, clinical 
symptoms are gradual and progressive and can differ between patients. Considering 
this, AD typically progresses in three stages (Figure 4): mild (early-stage), moderate 
(middle-stage) and severe (late-stage) (Feldman and Woodward 2005). In an early 
stage of AD, the disease starts progressing with a low accumulation of Aβ without 
causing symptoms. This is called the preclinical stage of the disease. As Aβ 
accumulation increases abnormally and the NFTs accumulate in neurons, they lose 
their ability to function efficiently. This begins in the hippocampus and entorhinal 
cortex, the brain areas responsible for forming memories.  The early symptomatic 
stage of AD is called mild cognitive impairment. The peculiar functional problems of 
AD patients are the signs and symptoms of moderate AD, which result from the 
progressive neuronal dysfunction and dead.  As more neurons die, the affected brain 
regions begin to atrophy.  By the late stage of the disease, neuronal damage is 
widespread leading to a significant shrinkage of the brain. AD patients are unable to 
communicate and are completely dependent on the others for their care.  
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Figure 4: Hypothetical model of dynamic biomarkers of the AD expanded to elucidate the clinical 
disease stage. Biomarkers change from normal to abnormal (y-axis) as a function of disease stage (x-
axis). Figure adapted from (Sperling et al. 2011). 
 
 
 
	
1.4.  Genetics of Alzheimer’s disease 
 
Memory loss, difficulty performing daily activities, behavior changes, etc., are 
common symptoms of AD patients. Although the symptoms and pathological 
characteristics are similar (Geert Van Gassen and Annaert 2003), there are two main 
categories of AD: familial and sporadic. Familial AD (FAD) represents less than 1% 
of all AD cases and is associated with heritable autosomal dominant mutations (G. 
Van Gassen and Van Broeckhoven 2000; Morris et al. 2012). The majority of AD 
cases are sporadic, without a particular genetic cause, beginning after age 65 and 
older.    
Mutations in three genes have been implicated in FAD: APP, Presenilin (PSEN) 1 
and PSEN2 (Goate et al. 1991; Levy-Lahad, Wasco, et al. 1995; Levy-Lahad, 
Wijsman, et al. 1995; Rogaev et al. 1995; Sherrington et al. 1995; Sherrington et al. 
1996). FAD patients have an earlier onset and faster progression of the disease 
compared to sporadic AD with the first symptoms manifesting approximately by the 
age of 40 (Rosenberg 2000). In general, these mutations lead to an increase of Aβ 
production, particularly Aβ42 (Johnston et al. 1994; Suzuki et al. 1994).  
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All FAD APP mutations influence the proteolytic processing of APP leading to an 
increase of Aβ generation, aggregation and plaque formation as they are positioned 
in or near the Aβ-coding exons (16 and 17) of APP which encode the Aβ sequence 
(Haass et al. 1994; Ishii et al. 2001; Schellenberg and Montine 2012).  
Most of PSEN mutations are single-nucleotide substitutions in subunits of the γ-
secretase enzymatic complex, which cleaves APP into two amyloid peptides (Aβ42 
and Aβ40) of different lengths. Biochemically, these mutations result in a partial loss 
of function in the γ-secretase complex (B. De Strooper et al. 1998) but from a genetic 
point of view, they result in a gain of toxic function. As a consequence, mutations in 
either PSEN or APP result in an increase of the ratio between Aβ42/Aβ40 by an 
increase in Aβ42 and/or a decrease in Aβ40 (Scheuner et al. 1996; Borchelt et al. 
1996).   
In the vast majority of AD cases, genetic risk factors increase the susceptibility for 
developing AD, though they are not the main cause. Neither genetic nor 
environmental factors acting separately can cause sporadic AD, both are necessary 
but not sufficient for the late-onset disease development.  
A large number of common variants or polymorphisms in different genes of AD 
patients have been identified as risk factors that can contribute to the development of 
sporadic AD. Genomic studies found several genes involved but among them the 
most relevant risk factor is the polymorphic gene encoding apolipoprotein E (ApoE) 
(Strittmatter, Saunders, et al. 1993; Rocchi et al. 2003). When the risk-conferring 
allele (ApoEε4) is present in heterozygous individuals it increases three-fold the risk 
for developing AD, while homozygous increase AD risk by 12-fold (Corder et al. 
1993; Strittmatter, Saunders, et al. 1993; Strittmatter, Weisgraber, et al. 1993).  
ApoE binds to Aβ influencing its degradation and clearance. Aβ degradation is 
influenced by ApoE isoform status through indirect mechanisms such as interaction 
with receptors/transporters responsible for endocytosis and lysosomal degradation. 
Thereby, ApoE sequesters Aβ preventing its clearance which results in a 
accelerated Aβ deposition and increases the rate of AD pathology (J. Kim, Basak, 
and Holtzman 2009; Castellano et al. 2011; Verghese et al. 2013).   
Another genome-wide association study in more than 70 000 individuals revealed 
sortilin-related receptor 1 (SORL1) as a sporadic AD risk gene (Lambert et al. 2013; 
Rogaeva et al. 2007; Lee et al. 2008). SORL1 is involved in the trafficking and 
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recycling of APP (Rogaeva et al. 2007) and therefore plays an important role for Aβ 
generation (Spoelgen et al. 2006; Offe et al. 2006; Schmidt et al. 2007).  
Recently, rare missenses mutations in the TREM2 protein have been related to an 
increased risk of sporadic AD (Guerreiro et al. 2013; Jonsson et al. 2013). TREM2 is 
a receptor expressed in microglia and regulates phagocytosis and suppresses 
inflammation (Guerreiro et al. 2013; Rohn 2013). Mutations in TREM2 cause an 
impairment of microglia phagocytosis thereby reducing the clearance of Aβ. These 
findings suggest that TREM2 is involved in neurodegeneration associated with the 
increased risk for sporadic AD.   
An interesting finding from a genetic analysis of an Iceland population identified a 
protective mutation (A673T) in the APP gene (Jonsson et al. 2012). The A673 
residue of APP lies very near the BACE1 site. The A673T mutation makes APP less 
favorable for cleavage by BACE1, resulting in less Aβ production. In addition, the low 
generation of Aβ peptides lowers Aβ aggregation (Maloney et al. 2014; Benilova et 
al. 2014). This mutation provides insight that reducing the β-cleavage of APP 
protects against AD, thus serving to the design of new preventing therapies.   
The majority of the identified genes affect Aβ production and clearance, emphasizing 
the contribution of this pathway in AD pathogenesis. Moreover, the identification of 
variants related to AD risk provides new insight for understanding the mechanisms 
underlying AD.  
 
1.5.  Mouse models of Alzheimer’s disease 
 
In order to study the mechanisms underlying the pathogenesis of AD, many different 
transgenic animals have been used. From worms, flies, fish to mice and rats, these 
models mimic the neuropathological alterations of AD, and enable us to study the 
temporal evolution of AD from its initial stages until the late stages.  
Transgenic mice are extensively used in research because their genetic modification 
is well established and they are easy to bread and house.  
The first transgenic mouse model (PDAPP) to study AD expressed high levels of 
human mutant APP (V717F) developed amyloid plaques between 6-9 months old 
and exhibit dystrophic neurites (Games et al. 1995). Later, two more mouse models 
expressing human APP mutations were created: the Tg2576 mouse (expresses 
APP695 with the Swedish double mutation) (Hsiao et al. 1996) and the APP23 
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mouse (expresses APP751 with the Swedish double mutation) (Sturchler-Pierrat et 
al. 1997). These three APP mouse models develop amyloid plaques, dystrophic 
neurites and gliosis.  
Nowadays, there are a variety of transgenic mouse models, which overexpress 
human APP with mutations associated with the development of FAD. However, 
mutations in APP are only responsible for a small fraction of FAD cases. Therefore, 
to represent better the progression of AD, it was necessary to generate mouse 
models crossing APP mutant lines with lines carrying mutations in the PSEN genes 
(Holcomb et al. 1998). Double transgenic animals carrying both APP and PSEN1 
have increased Aβ42 levels and show development of the disease at young ages 
(Seabrook and Rosahl 1999). In fact, crossings with PSEN mutations favor the 
productions of Aβ, in particular Aβ42 peptide (Tara L. Spires and Hyman 2005). 
However, none of them develop NFTs.  
A double transgenic progeny from a cross between the line Tg2576 and the mouse 
expressing Tau with the P301L mutation, developed the same amount of plaques as 
the Tg2576 mice but showed enhanced neurofibrillary tangle pathology compared to 
the P301L mouse (Lewis et al. 2001). A triple transgenic model was created to 
express APP, PSEN1 and Tau mutations (3xTg), which displays both plaque (from 6 
months of age) and tangle pathology (from 12 months of age) (Oddo, Caccamo, 
Shepherd, et al. 2003; Oddo, Caccamo, Kitazawa, et al. 2003).    
In 2006, a new transgenic mouse was generated that coexpresses both APP bearing 
the Swedish mutation and PSEN1 containing an L166P mutation (APPPS1) (Radde 
et al. 2006). The Aβ deposition in the APPPS1 mice begins at 6 weeks of age in the 
cortex and 3-4 months of age in the hippocampus. Amyloid-associated pathologies 
including dystrophic neurites, hyperphosphorylated tau and robust gliosis, with 
neocortical microglia number increasing threefold from 1 to 8 months of age (Radde 
et al. 2006).  
Later, another new transgenic mouse model with five FAD mutations (5xFAD) was 
generated. Although tangles are absent, this model develops an early and severe 
plaque pathology (around 2 months of age), as well as synapse degeneration 
(Oakley et al. 2006). Nevertheless, researchers are still not able to generate a 
mouse model that reproduces all aspects of AD like amyloid plaques, dystrophic 
neurites, NFTs, neuronal loss, gliosis, synaptic loss and cognitive impairment. And 
this is the limitation of using a rodent to reproduce a human disease that needs 
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decades to develop (McGowan, Eriksen, and Hutton 2006). Notwithstanding, the 
current different transgenic mouse models mimic a range of AD-related pathologies 
and thus provide significant insights into the pathophysiology of Aβ toxicity and are 
useful in clinical trials of therapeutic modalities that aim to delay, prevent or stop the 
disease.  
Accordingly to the aim of this study, the AD mouse model used was the 
APPSwe/PSEN1dE9 (described in chapter 3.1).    
 
 
2. Amyloid pathology 
 
 
2.1. Amyloid Precursor Protein 
 
 
  Structure and function  2.1.1
 
The human APP gene is located on chromosome 21. There are three major isoforms 
arising from alternative splicing: APP696, APP751 and APP770 (containing 695, 751 
and 770 amino acids respectively) (Goate et al. 1991). 
APP is evolutionary conserved and detected in lower organisms and in a variety of 
mammals. The protein family of APP includes APP-like protein 1 and 2 (APLP1 and 
APLP2) in mammals (Wasco et al. 1992; Wasco et al. 1993; Coulson et al. 2000),  
APPL in Drosophila melanogaster (Rosen et al. 1989) and APL-1 in Caenorhabditis 
elegans (Daigle and Li 1993). All of them are type I transmembrane proteins with a 
large extracellular N-terminal and short cytoplasmatic C-terminal. The processing of 
these proteins is in a similar way leading to the secretion of large ectodomains, 
however only the APP gene contains the Aβ domain (Jacobsen and Iverfeldt 2009).  
The biological function of APP remains undetermined, although several studies have 
been suggesting a role of APP in processes of cellular adhesion, neuronal survival, 
neurite outgrowth, synaptogenesis, neuronal protein trafficking along the axon, 
modulation of synaptic plasticity, transmembrane signal transduction, calcium 
metabolism, etc. (Jacobsen and Iverfeldt 2009; Zheng and Koo 2006).  
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  Proteolytic processing of APP and Aβ generation  2.1.2
 
APP is synthesized in the endoplasmic reticulum (ER) and then is transported to the 
trans-Golgi-network (TGN) through the Golgi apparatus (Xu et al. 1997; Hartmann et 
al. 1997; Greenfield et al. 1999). Generation of Aβ peptides occurs in the ER (for 
Aβ42) and Golgi/TGN (for Aβ40) (Greenfield et al. 1999). 
The proteolytic processing of APP is performed sequentially by three proteinases (α-
,β- and γ-secretases) and can be divided in two different pathways: the non-
amyloidogenic pathway and the amyloidogenic pathway (Figure 5) (Selkoe 1994a; 
Selkoe 1994b; Selkoe 1994c; B. De Strooper and Annaert 2000).  
 
 
Figura 5: Proteolytic processing of APP within the non-amyloidogenic (left) and amyloidogenic (right) 
pathways. Figure adapted from (LaFerla, Green, and Oddo 2007). 
 
 
In the non-amyloidogenic pathway, the cleavage of APP is mainly performed by α-
secretase that cleaves within the Aβ domain (between the Lys16 and Leu 17) 
precluding the formation of Aβ (Anderson et al. 1991; Sisodia 1992). This cleavage 
results in the release of a large soluble ectodomain of APP named sAPPα and the 
generation of a truncated membrane anchored C-terminal fragment of 83 amino 
acids named C83 (Sisodia et al. 1990; Esch et al. 1990; Sisodia 1992). The C83 
fragment is further processed by γ-secretase generating the small P3 peptide which 
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apparently is pathologically irrelevant (Haass and Selkoe 1993; Checler 1995). The 
APP cleavage by α-secretase destroys the Aβ sequence precluding the generation 
of intact Aβ (Gandy et al. 1994).  
In the amyloidogenic pathway, the cleavage of APP is firstly performed by β-
secretase and results in the generation of Aβ. The β-secretase, known as β-site APP 
cleaving enzyme 1 (BACE1) (R. Vassar et al. 1999; R. Yan et al. 1999a; Sinha et al. 
1999), initiates the cleavage of APP generating a truncated soluble ectodomain, 
named sAPPβ, and a C-terminal fragment, named C99 (or βCTF), which is retained 
in the membrane. C99 fragments are further proteolyzed by γ-secretase, which 
generates two variants of Aβ (Aβ42 and Aβ40) and a residual C-terminal fragment 
named AICD (APP intracellular domain). The variant Aβ42 has more tendency to 
aggregate and form fibrils and is also considered more toxic than the shorter Aβ40 
(Burdick et al. 1992; Jarrett, Berger, and Lansbury 1993). The α-secretase can 
compete with β-secretase for the cleavage of APP (Skovronsky et al. 2000) leading 
to an imbalance between the both cleavage events.  
 
 
  BACE-1 2.1.3
 
β-secretase activity mediates the initial and rate-limiting factor for Aβ generation. 
Several studies were undertaken in order to define the characteristics of its activity. 
The highest levels of β-secretase activity were predominantly found in neurons 
(Seubert et al. 1993; Zhao et al. 1996) and only membrane-bound subtracts were 
efficiently cleaved (Citron et al. 1992; Citron, Teplow, and Selkoe 1995). This 
indicates that β-secretase is likely to be a membrane-bound protease or closely 
associated with a membrane protein. Additionally, maximal activity of β-secretase 
was detected at acidic pH, (Haass et al. 1993; Haass, Capell, et al. 1995; Knops et 
al. 1995), and it was suggested that the active site of this enzyme is located within 
the lumen of acidic intracellular compartments because the highest β-secretase 
activity was within the subcellular compartments of the secretory pathway, including 
the Golgi apparatus and endosomes (Koo and Squazzo 1994; Haass, Lemere, et al. 
1995).   
Between 1999-2000, five independent groups identified BACE1 (also named as 
Asp2 or memapsin 2) as the β-secretase because indeed it exhibited all the known 
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properties of β-secretase (Hussain et al. 1999; Sinha et al. 1999; R. Vassar et al. 
1999; R. Yan et al. 1999b; Lin et al. 2000).  
BACE1 is a transmembrane aspartic protease composed of 501 amino acids and 
has a N-terminal signal sequence (residues 1-21), a pro-peptide domain (residues 
22-45), a single transmembrane domain near the C-terminus (residues 455-480) and 
a cytoplasmic tail (Haniu et al. 2000; Benjannet et al. 2001). The correct topological 
orientation for APP cleavage at the β-secretase site is provided by the location of 
BACE1 active site within the lumen of intracellular compartments (Haniu et al. 2000).  
Besides BACE1, a homologous protease named BACE2 was also identified, 
however is not involved in Aβ production but can lead to its decrease (Robert Vassar 
2004). BACE2 can lower Aβ levels via α-secretase-like cleavage of APP within the 
Aβ sequence (Hussain et al. 2000; R. Yan et al. 2001; Fluhrer et al. 2002) or work as 
an Aβ-degrading protease regulating the Aβ levels through its high catalytic 
efficiency in degrading Aβ intracellularly (Abdul-Hay et al. 2012).   
The BACE1 is ubiquitously expressed in the brain and pancreas (R. Vassar et al. 
1999). BACE1 levels are elevated in neurons and especially at presynaptic terminals 
(Zhao et al. 2007; Kandalepas et al. 2013). Elevated expression and activity levels of 
BACE1 were reported in postmortem brains and cerebrospinal fluid (CSF) from 
sporadic AD patients (Yang et al. 2003). Accumulation of BACE1 begins to increase 
in parallel with amyloid pathology and is observed predominantly in dystrophic 
presynaptic terminals surrounding amyloid plaques in brains of AD patients and AD 
mouse models (Zhao et al. 2007; Kandalepas et al. 2013) suggesting the strong 
contribution of BACE1 in the development AD.  
BACE1 and APP are separately internalized from the plasma membrane, through 
different routes, and meet in the early endosomal compartments in order for BACE1 
to cleave APP (Rajendran and Annaert 2012; Robert Vassar et al. 2014). Endosomal 
BACE1 is sorted to lysosomes for its degradation or, alternatively, is transported 
from early endosomes via Rab11 to recycling endosomes through which it is sorted 
to the cell surface and then re-internalized back to early endosomes (Rajendran and 
Annaert 2012). Dysfunctions in the endocytic pathway were observed in brains of 
sporadic AD patients (A. M. Cataldo et al. 2000; Anne M. Cataldo et al. 2004). 
Associated with this, an increased endocytic activity enhance the amyloidogenic 
processing of APP, potentiating the mechanism underlying AD progression 
(Ginsberg et al. 2010). Moreover, accumulation of APP and the βCTF are 
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considered the cause of endocytic pathway dysfunction (Jiang et al. 2010; S. Kim et 
al. 2016). These findings support the hypothesis that altered proteolysis of APP and 
dysfunction of the endocytic pathway are linked with the abnormal BACE1 activity 
and increased Aβ production in AD.   
Given that BACE1 is the major β-secretase in the brain and is highly contributing to 
the pathology of AD, a rising number of BACE1 inhibitors have been generated and 
undergo clinical trials. 
 
 
2.2.  Amyloid peptide 
 
2.2.1. Aggregation and accumulation of Aβ 
 
The Aβ peptide was identified in the mid-80s, for the first time, as component of 
extracellular amyloid plaques (Glenner and Wong 1984; Masters et al. 1985; Selkoe 
et al. 1986; Weidemann et al. 1989).   
The aggregation of Aβ, especially Aβ42, follows a defined pathway, which results in 
the formation of amyloid fibrils and plaques. This aggregation starts with Aβ 
monomers, which aggregate via several intermediate steps and finally form large 
fibrils with an amyloid structure (Figure 6). Amyloid is defined as “any proteinaceous 
polymer having a β-pleated sheet conformation that accumulates extracellularly” 
(Fiala 2007).  
 
 
Figure 6: Aβ aggregation process. Aβ is released as a monomer which can aggregate to form 
oligomers and protofibrils. Protofibrils aggregate to form mature fibrils.  
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The Aβ peptide is produced as soluble monomers, but quickly aggregates to form 
multimeric structures. These structures range from dimers and trimers, of low 
molecular weight (soluble oligomeric species), protofibrils and fibrils of higher 
molecular weight (insoluble species) that are the basic component of plaques (Cruz 
et al. 1997; Walsh et al. 1999; Bitan et al. 2003; Ahmed et al. 2010). The fibrillization 
reaction from toxic protofibrillar intermediates into mature amyloid fibrils can be 
reversed towards soluble Aβ protofibrils and Aβ monomers (Figure 6) (Martins et al. 
2008; Grüning et al. 2013). These dissociations demonstrate that amyloid plaques 
are the major source of soluble toxic Aβ aggregates.   
Amyloid deposition typically occurs via a nucleation-growth mechanism that involves 
the formation of several intermediates, including soluble oligomers and protofibrils, 
and has an initial lag-phase due to the thermodynamic unfavorable nucleation event 
(A. Lomakin et al. 1996; Murphy 2002; Chiti and Dobson 2006). Once nucleation 
occurs, the aggregation process continues via an exponential growth phase in 
parallel association with the addition of monomers into aggregate structures. In vitro 
and in vivo experiments of Aβ aggregation demonstrated that the initial lag-phase 
can be circumvented by seeding pre-formed Aβ aggregates which induces and 
accelerates the process of amyloid plaque deposition (Jarrett and Lansbury 1992; 
Lansbury 1997; Aleksey Lomakin et al. 1997; Hu et al. 2009; Langer et al. 2011; 
Hamaguchi et al. 2012).  
Insoluble Aβ aggregates appeared to be the most potent inducer for plaque 
deposition, but others studies revealed that seeding of Aβ oligomers contributed to 
the plaque formation (Gaspar et al. 2010). Moreover, other in vitro and in vivo 
studies showed that Aβ oligomers bind exclusively to synaptic terminals causing 
alterations of the synapse structure, which leads to synapse loss (Lacor et al. 2007). 
Supporting the toxic effect of oligomers at the synapse, oligomers induced loss of 
hippocampal synapses (Brouillette et al. 2012) through modulation of NMDA 
receptors (Shankar et al. 2007). Synapse loss was associated with reduced dendritic 
spine density and disruption of memory and learning which might result from 
enhanced long-term depression mediated by Aβ oligomers (Shankar et al. 2008).  
Although compelling evidence suggest that fibrillar aggregation and accumulation of 
amyloid aggregates might be the leading cause for neurodegeneration in AD, the 
recent evidences have shift toward defining soluble Aβ oligomers as the toxic agent 
	 19	
rather than plaques bringing up controversies surrounding the amyloid cascade 
hypothesis.  
 
 
2.2.2. The amyloid cascade hypothesis 
 
John Hardy and Gerald Higgins firstly described the amyloid cascade hypothesis in 
1992 (J. A. Hardy and Higgins 1992). The amyloid cascade combines 
histopathological and genetic information, and postulates that the deposition of Aβ 
peptide in the brain parenchyma is the crucial step for the sequence of events that 
ultimately leads to AD.  
According to the hypothesis, Aβ and its multimeric species, triggers a cascade of 
events producing the pathological characteristics of amyloid plaques and tau 
aggregates and, ultimately, result in synapse dysfunction and neuronal loss. As Aβ 
accumulates, the amyloid burden increases and the ongoing neurodegeneration 
leads to the progression of AD (Figure 7). 
 
 
Figure 7: Amyloid cascade hypothesis. Aβ overproduction and/or aggregation trigger the 
downstream neuronal events and neurodegeneration in AD. 
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Autosomal dominant mutations that cause early-onset of FAD have supported this 
hypothesis. These mutations influence the cleavage of Aβ, leading to its 
accumulation and aggregation into amyloid plaques. 
Mutations in the gene encoding for APP or PSEN1 often increase the production of 
Aβ and/or modify the ratios of Aβ species cleaved from APP. These observations 
also led to the articulation of the amyloid cascade.  
Another putative evidence in support of the hypothesis was the observation of AD 
like-pathology in individuals with trisomy 21 (Down’s Syndrome) (Zigman et al. 
2008). Down’s syndrome occurs when three copies of the Chromosome 21 are 
inherited. The gene encoding for APP lies in Chromosome 21, therefore Down’s 
individuals have a triple copy of APP, explaining the excess Aβ production (Zigman 
et al. 2008).    
Although the risk genes mentioned previously contribute for early-onset FAD, a 
strong genetic risk factor for late-onset of AD with no direct association to the APP 
gene or its processing enzymes, also support the amyloid hypothesis. This risk factor 
is the ApoE, which contributes to reduction of Aβ clearance, increasing its levels and 
aggregation. However, the pathway(s) by which ApoE may increase Aβ levels are 
still under debate. 
The amyloid cascade hypothesis has widely influenced the academia research and 
the pharmaceutical industry, although some changes to the hypothesis have 
occurred since recent data suggested soluble Aβ oligomers as the toxic agent rather 
than plaques (Glabe 2006; Shankar et al. 2007; Bernstein et al. 2009; Kuperstein et 
al. 2010). Although the hypothesis has been modified, the mechanisms of 
synaptotoxicity and neurotoxicity mediated by the soluble forms of multimeric Aβ 
peptide species remain incompletely understood, making this topic controversial in 
the field. Nevertheless, the theory and the way of interpreting data remains the 
same, i.e. Aβ production and accumulation as oligomers or fibrillar plaques trigger 
AD.   
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2.3.  Amyloid plaques 
 
Aβ plaques are one of the central pathologies of AD. Plaques are extracellular 
deposits of aggregated Aβ, typically within a spherical region, and are abundant in 
the cortex of AD patients (Fiala 2007). The main components of plaques are the Aβ 
fibrils, which can be visualized through optical and electronic microscopy (Figure 2).  
As Aβ production is enhanced in AD, its accumulation leads to plaque formation. 
Several groups have been investigating the kinetics of Aβ aggregation into amyloid 
plaques in AD mouse models (Liebscher and Meyer-Luehmann 2012). These 
studies revealed that upon Aβ deposition, plaques are very small and then gradually 
increase their size during ageing (Hyman et al. 1995; P. Yan et al. 2009; Hefendehl 
et al. 2011; Bittner et al. 2012). Moreover, a new mechanism for plaque growth, 
called clustering of plaques, proposed that existent plaques contribute to the 
formation and growth of new plaques in their vicinity (McCarter et al. 2013). Recent 
in vivo data demonstrated that the kinetics of plaque volume is divided in three 
phases: cubic, transition and saturation. First, the high concentration of Aβ leads to 
the formation of several new plaques (cubic phase). During the transition phase, the 
plaque growth rate increases strongly causing an increase of plaque volume. Later, 
in the saturation phase, plaques grow slower due the high density of plaques. At this 
stage, as most of the available Aβ is bound in plaques at this stage, there is not 
enough free available Aβ to promote new plaque formation. Furthermore, not 
enough Aβ is available to keep up a constant growth rate (Burgold et al. 2014).  
 
2.3.1. Dense-core and diffuse plaques 
 
Amyloid plaques are classified in dense-core and diffuse based on their morphology 
and Thioflavin-S and Congo Red staining’s (Figure 8) (Rak et al. 2007).  
 
 
Figure 8: Types of amyloid plaques. (A-B) Dense-core plaques and (B) diffuse plaques 
immunostained with anti-Aβ antibody (4G8). Figure adapted from (Rak et al. 2007) 
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Dense-core plaques consist of fibrillar Aβ deposits with a compact core that is well 
stained with Thioflavin-S and Congo Red. Dense-cored plaques are typically 
surrounded by dystrophic neurites, activated microglia, reactive astrocytes and 
associated with synapse loss.  They correlate with cognitive impairment in AD 
patients (Itagaki et al. 1989; Masliah et al. 1994; Pike, Cummings, and Cotman 1995; 
Knowles et al. 1999; Urbanc et al. 2002; Sasaki et al. 2002; Vehmas et al. 2003).  
Diffuse plaques consist of amorphous Aβ (Tagliavini et al. 1988; Yamaguchi et al. 
1989) and are proposed to be the precursors of dense-cored plaques (Armstrong 
1998). These plaque types are generally non-neuritic and not associated with 
synapse loss. Thereby, they are common found in brains of cognitively intact aged 
people (Mirra 1997; Rak et al. 2007; A. Serrano-Pozo et al. 2011). Contrary to 
dense-core plaques, these amyloid deposits are Thioflavin S and Congo Red 
negative. 
Structurally, dense-core and diffuse plaques are very different. As verified by an anti-
Aβ antibody therapy, APP transgenic mice treated with the antibody showed a 
reduced plaque load with preferential clearance of diffuse plaques (A. Wang et al. 
2011).   
Only dense-core plaques and not diffuse plaques are associated with neuritic and 
inflammatory pathology in AD patients as well as in AD mouse models. However, 
transgenic mouse models expressing FAD mutations develop different types of 
amyloid plaques. APP23 mice mice developed both Congo Red positive dense-core 
plaques and diffuse plaques (Sturchler-Pierrat et al. 1997; Stalder et al. 1999) while 
Tg2576, PSAPP and APPPS1 mainly developed dense-core plaques (Sasaki et al. 
2002; Kumar-Singh et al. 2005; Pereson et al. 2009). 
Some AD patients with PSENΔE9 develop atypical neuropathology for AD, including 
large “cotton wool” amyloid deposits in the cortex with a relative absence of dense-
core plaques (Crook et al. 1998; Verkkoniemi et al. 2001). “Cotton wool” plaques are 
large, ball-like plaques lacking dense amyloid cores that displace adjacent 
structures. However, APPSwe/PSEN1dE9 mice do not display “cotton wool” plaques 
but have the typical AD dense-core plaques (Jankowsky et al. 2004).  
The type of plaque is important for the pathological diagnosis of AD because it is a 
relatively common to find diffuse plaques the brain of cognitively intact elderly 
people. New insights into the mechanisms that lead to the formation of different 
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amyloid plaques would contribute to a better understanding of pathological AD 
progression. 
 
 
2.3.2. Plaque-associated axonal dystrophies 
 
Plaque-associated neuritic dystrophies (Figure 9) are one of the diagnostic brain 
lesions observed in AD patients and represent the most notorious evidence that Aβ 
might induce neurotoxicity. These axonal and dendritic injuries, generally found in 
large numbers in the cortex, causing a permanent disruption of neuronal connections 
(D. W. Dickson 1997; Vickers et al. 1996; J. Hardy and Selkoe 2002; Tsai et al. 
2004; Bittner et al. 2012).  
 
 
Figure 9: Illustration of dystrophic neurites surrounding an amyloid plaque. Drawings from 
Simarro (left) and Oskar Fischer (right). Figure adapted from (Cajal and May 1991). 
 
 
Dystrophic neurites are often swollen and tortuous axons (axonal dystrophies), with 
variable morphology and composition depending on the pathological stage of AD 
(Vickers et al. 1996; Su, Cummings, and Cotman 1998; Knowles et al. 1999; 
Woodhouse et al. 2009; Wu et al. 2010; Mitew et al. 2013). Axonal dystrophies are 
intimately associated with extracellular deposits of Aβ, principally amyloid fibrils 
(Geddes, Anderson, and Cotman 1986; Masliah et al. 1991; Masliah et al. 1994; 
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Vickers et al. 1996; Su, Cummings, and Cotman 1998; T. C. Dickson et al. 1999; 
D’Amore et al. 2003; R. Brendza 2003; Tsai et al. 2004; T. L. Spires 2005; Monica 
Garcia-Alloza, Dodwell, et al. 2006; Woodhouse et al. 2009). They can occur both 
within the amyloid plaque and/or immediately surrounding it.    
The accumulation of Aβ in the brain of AD patients results from the proteolytic 
processing of APP by BACE1 and γ-secretase (Bart De Strooper 2010). The role of 
BACE1 in AD came from the analysis of postmortem brains and CSF from AD brains 
where BACE1 levels and activity are increased (Fukumoto et al. 2002; Holsinger et 
al. 2002; Tyler et al. 2002; Yang et al. 2003; Li et al. 2004; Harada et al. 2006). 
Elevation of BACE1 is not uniform throughout the brain, but is predominantly 
concentrated in dystrophic presynaptic terminals surrounding amyloid plaques (Zhao 
et al. 2007; Kandalepas et al. 2013). BACE1 and APP strongly accumulate in 
dystrophies (Cras et al. 1991; Kandalepas et al. 2013) and potentiates the 
generation of BACE1-cleaved APP products, including Aβ42 that exacerbates 
plaque growth (Sadleir et al. 2015; Sadleir et al. 2016).      
Although most of the previous studies have focused on the analysis of the 
localization pattern of increased BACE1 in dystrophic axons surrounding plaques, 
the mechanisms for axonal dystrophy formation remained unclear until recently. Two 
comprehensive studies provided new insights into the fundamental mechanisms for 
axonal dystrophy formation, Aβ generation and plaque growth. Importantly, they 
revealed that the formation of axonal dystrophies is caused by a feed-forward 
mechanism of increased accumulation of BACE1, APP and lysosomes (preferentially 
lysosome precursors) as a result of a local impairment in the retrograde axonal 
transport. Accumulation of immature lysosomes at amyloid plaques acts as sites of 
Aβ synthesis increasing its accumulation. The increase of Aβ generation and plaque 
growth cause axonal microtubule disruption and microtubule-based transport 
impairment leading to the accumulation of BACE1, APP and Aβ generation 
(Gowrishankar et al. 2015; Sadleir et al. 2016).  
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3. Investigating plaque-associated presynaptic dystrophies 
 
Previous studies have reported in vivo evidence for the formation of axonal 
dystrophies near plaques and the possibility of recovery after different treatments (M. 
Garcia-Alloza et al. 2007; R. P. Brendza et al. 2005; T. L. Spires 2005; Tsai et al. 
2004; D’Amore et al. 2003). However, these studies did not monitor the formation of 
axonal dystrophies and plaque growth kinetics over a long observation period 
including a long-term therapeutic strategy.  
 
3.1.  The APPSwe/PSEN1dE9 mouse model 
 
Transgenic mouse models recapitulate some of the pathological aspects of AD 
allowing the analysis of disease initiation and progression.  
The APPSwe/PSEN1dE9 mouse model is double transgenic mouse that was 
created by breeding mice that express mutant APP with mice that express mutant 
PSEN1. 
The Swedish mutation (APPSwe) causes an increase of the total Aβ generation 
(Borchelt et al. 1996; Savonenko et al. 2005). Expressing human PSEN1 lacking 
exon 9 mimics the FAD-associated mutation. Plaque depositions in 
APPSwe/PSEN1dE9 mice form at six months of age with an even greater amyloid 
burden at 18 months (Savonenko et al. 2005).  
Although some AD patients with ΔE9 develop atypical neuropathology for AD, 
APPSwe/PSEN1dE9 mice display typical dense-core plaques in the cortex and 
develop axonal dystrophies surrounding plaques (Jankowsky et al. 2004; Kitazawa, 
Medeiros, and LaFerla 2012).   
The generation of a new mouse model which axons, dendrites and dendritic spines 
express GFP-M (Feng et al. 2000) enabled us to generate the mouse model used in 
this study (APPSwe/PSEN1dE9 x GFP-M). The APPSwe/PSEN1dE9 crossed with 
the GFP-M mouse line leads to a sparse labeling of pyramidal neurons in neocortex 
and hippocampus (Feng et al. 2000) allowing us to study the formation of axonal 
dystrophies associated with plaque development over time. Given that this mouse 
model develop plaques later than the APPPS1 mouse model (Radde et al. 2006) it 
recapitulates the gradual progression of AD, which makes a good model to study 
plaque-associated axonal dystrophies.  
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3.2.  In vivo two-photon imaging in mouse models of AD 
 
BACE1 is the major β-secretase enzyme required for the generation of Aβ peptides. 
Therefore, has emerged as a promising target for the treatment of AD. To investigate 
the pharmacological effect of BACE1 inhibition on the formation of axonal 
dystrophies and plaque development, long-term in vivo 2-photon imaging was used 
to obtain the majority of the results for this thesis. The 2-photon microscopy allowed 
to image single axons and monitors the formation of axonal dystrophies and plaque 
development before and after BACE1 inhibitor administration, in the same mouse 
model, over a long period of time. Combining 2-photon microscopy with a therapeutic 
strategy is important to interpret and characterize the effect of BACE1 inhibition in a 
mouse model of AD. By implanting a cranial window over the somatosensory cortex 
and applying (Figure 10) 2-photon microscopy (Holtmaat et al. 2009) it is possible to 
perform long-term imaging of neuritic structures and study the dynamics of cortical 
pathology at a far greater imaging depth compared to conventional confocal 
microscopy. Two-photon microscopy uses pulsed infrared light with a long 
wavelength to excite fluorophores preventing the effect of tissue light scattering at 
greater depths. The fluorophores absorb two photons nearly simultaneously, instead 
of the one in conventional microscopy. The non-linear effect of 2-photon excitation 
diminishes the area of out of focus-excitation compared with conventional 
fluorescence microscopy, therefore reducing out of focus excitation and 
photobleaching. 
 
 
Figure 10: Images of a 4-mm cranial window implantation over the somatosensory cortex. (A) 
Head fixation. (B) Trepanation of the skull. (C) Image of the cranial window after the piece of the skull 
has been removed and brain after the cleaning procedure. (D) 4-mm cranial window. (E) Image of the 
cranial window after the application of dental cement over the skull. (F) Cranial window four weeks 
after surgery. Scale bars: 1 mm and 20 mm. 
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Fluorescent dyes such as Methoxy-X04 cross the blood brain barrier and can be 
repeatedly administrated via peripheral injection. Methoxy-X04 labels amyloid fibers 
allowing the visualization of individual plaques over time (Klunk et al. 2002; 
Hefendehl et al. 2011).  
Generation of mice that express eGFP in neurons enabled the visualization of 
neurites and dendritic spines using 2-photon microscopy and the study of the 
relationship between amyloid plaques and associated pathology (Monica Garcia-
Alloza, Dodwell, et al. 2006; Meyer-Luehmann et al. 2008; Bittner et al. 2012).  
Despite the limited imaging area, 2-photon microscopy is a powerful tool to image 
the dynamics of axonal dystrophies and the kinetics of amyloid plaques during a long 
period of time.     
 
  
3.3.  BACE1 inhibitor – a prime drug target for AD   
 
Previous studies have reported in vivo, evidences about the possibility for recovery 
of the formation of axonal dystrophies near plaques after different treatments. (M. 
Garcia-Alloza et al. 2007; R. P. Brendza et al. 2005; T. L. Spires 2005; Tsai et al. 
2004; D’Amore et al. 2003). 
Given that BACE1 is the required initiator enzyme for Aβ generation and therefore 
rate-limiting in the production of Aβ (R. Vassar et al. 1999; Ghosh, Brindisi, and Tang 
2012), it is one of the major drug targets for the treatment of AD. 
In BACE1-null mice, Aβ generation is abolished, and Aβ is significantly reduced in 
BACE1 heterozygous mice (McConlogue et al. 2007). Based on these data, several 
pharmaceutical companies have developed potent blood brain barrier (BBB)-
penetrant BACE1 inhibitors that are being tested at various stages of clinical trials 
with the ambition that potent inhibition of BACE1 activity in humans will decrease Aβ 
generation, benefit synaptic function and stop the progression of the disease 
(Riqiang Yan and Vassar 2014).  
In this study we used the novel BACE1 inhibitor – NB360, described in 2015 by 
(Neumann et al. 2015) (Figure 11). NB360 is a potent and BBB-penetrant BACE1 
inhibitor which greatly reduced Aβ and neuroinflammation in rodent and non-rodent 
models (Neumann et al. 2015).   
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Figure 11: Structure of the BACE1 inhibitor NB360. NB360 is orally administrated by food pellets 
(Neumann et al. 2015).  
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MATERIAL AND METHODS 
 
	
1. Genotyping  
 
A small section of tail was removed from each mouse for genotyping. First, the DNA 
was extracted following instructions of the Invisorb® DNA Tissue HTS 96 Kit/C 
(Stratec molecular).  The tissue was incubated in 400 µl Lysis Buffer G (inclusive 
Proteinase K) at 52°C under continuously shaking until lysis is completed and 
centrifuge at 1.700 x g (4.000 rpm) for 10 min and RT. Supernatant was carefully 
transferred into a 2 ml Collection Plate and 200 µl Binding Buffer A were added to 
each well of the 2 ml Collection Plate and mix it by pipetting up and down. The plate 
was centrifuged at 1.700 x g (4.000 rpm) for 5 min at RT. The filtrated was discarded 
and the plate air-dried.  The pellet was re-suspended in 550 µl of Wash Buffer and 
centrifuged at 1.700 x g (4.000 rpm) for 5 min at RT followed by another 
centrifugation for at least 15 min at max. 1.700 x g (4.000 rpm).  To finalize the DNA 
extraction, 100 µl prewarmed elution buffer (52°C) was added in each well and 
centrifuged for 5 min at 1.700 x g (4.000 rpm). The extracted DNA was subjected to 
a polymerase chain reaction (PCR) to amplify PSEN1 gene - if present. The PCR 
solution consisted of: 12,5 µl OneTaq HotStart QuickLoad, 0,5 µl of each forward 
primer (CTA GGC CAC AGA ATT GAA AGA TCT; AAT AGA GAA CGG CAG GA), 
0.5 µl of each reverse primer (GTA GGT GGA AAT TCT AGC ATC ATC C; GCC 
ATG AGG GCA CTA AT), 0,5 µl template DNA and 10 µl distilled water. This 
solution was placed in a thermocycler andthe following PCR program was used:  
 
Step Temperature (°C) Time Repeat 
1 94 3 minutes 1x 
2 94 30 seconds  
27x 3 54 1 minute 
4 68 40 seconds 
5 68 5 minutes 1x 
6 10 1 min  
 
Another PCR to amplify eGFP gene - if present, consisted of: 12,5 µl OneTaq 
HotStart QuickLoad, 0,5 µl of forward primer (AAG TTC ATC TGC ACC ACC G), 0.5 
µl of reverse primer (TCC TTG AAG AAG ATG GTG CG), 0,5 µl template DNA and 
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11 µl distilled water. This solution was placed in a thermocycler. The following PCR 
program was used:  
 
Step Temperature (°C) Time Repeat 
1 94 3 minutes 1x 
2 94 30 seconds  
27x 3 60 1 minute 
4 68 20 seconds 
5 68 2 minutes 1x 
6 10 1 min  
    
The PCR samples were separated by gel electrophoresis using a 1,5% agarose 
containing SYBR® Gold Nucleic Acid Gel Stain in TAE buffer as the running buffer. 
Between 120-195 V was applied for approximately 60-90 minutes and the gel 
imaged with a UV light source. A photograph was taken for documentation. 
 
2. Animals and Housing 
 
The studies were carried out in accordance with an animal protocol approved by the 
Ludwig-Maximilians-University Munich and the government of Upper Bavaria (Az. 
55.2-1-54-2532-62-12). The cranial window preparation and in vivo imaging were 
performed under anesthesia, and all efforts were made to minimize suffering of the 
animals. 
Mouse lines APPSwe/PSEN1dE9 (Jankowsky et al. 2004) and GFP-M (Feng et al. 
2000) were used in this study. The double transgenic APPSwe/PSEN1dE9 mouse 
line expresses a chimeric protein of mouse/human amyloid precursor 
(Mo/HuAPP695swe) and mutant human presenilin 1 (PSEN1-dE9) both under the 
control of the mouse prion protein promoter resulting in abundant amyloid plaques in 
neocortex and hippocampus starting at the age of 6 months (Jankowsky et al. 2004; 
Savonenko et al. 2005). In the GFP-M mouse line the green fluorescent protein 
(eGFP) is expressed under control of Thy1.2 promoter which leads to a sparse 
labeling of pyramidal neurons in neocortex and hippocampus (Feng et al. 2000). 
Heterozygous mice of APPSwe/PSEN1dE9 were crossed with heterozygous GFP-M 
mice resulting in triple transgenic APPSwe/PSEN1dE9 x GFP-M offspring, which 
were inbred. Heterozygous triple transgenic mice of mixed gender were used for 
experiments at indicated ages described below. Mice were group-housed under 
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pathogen-free conditions until surgery, after which they were singly housed in 
standard cages with food and water ad libitum. 
 
3. BACE1 Inhibitor 
 
NB360 was synthesized following the schemes provided by Novartis (Neumann et al. 
2015) and formulated in 10% (w/v) 2-hydroxypropyl-beta-cyclodextrin. Both inhibitor 
and vehicle were administered orally via the food pellets at 0.25 g/kg body weight. 
Assuming 30g body weight and 4 to 5 g daily food consumption, the mice received a 
daily dose of 33 to 42 mg/kg body weight for up to 3 months. The pharmacological 
properties of NB360 have been extensively characterized previously (Neumann et al. 
2015).  
 
4. Two-Photon in vivo imaging 
 
For in vivo imaging, a chronic cranial window was implanted as described previously 
(Fuhrmann et al. 2007; Holtmaat et al. 2009). Surgery was performed in eight 5 
months-old APPSwe/PSEN1dE9 x GFP-M. Mice were anesthetized with an 
intraperitoneal injection of ketamine/xylazine (14 mg/Kg body weight; WDT/Bayer 
Health Care). Additionally, dexamethasone (6 mg/kg body weight; Sigma) was 
intraperitoneally administered immediately before surgery. Utilizing the open-skull 
preparation, a cranial window was placed above the somatosensory cortex. For 
repositioning during repetitive imaging a small titan bar was glued next to the 
window. After surgery, mice received subcutaneously analgesic treatment with 
carprophen (7.5 mg/Kg body weight; Pfizer) and antibiotic treatment with cefotaxim 
(250 mg/Kg body weight; Pharmore). 
Weekly imaging started 4 weeks post-surgery (recovery period) utilizing a LSM 7 MP 
setup (Zeiss) being equipped with a MaiTai laser (Spectra Physics) followed by 
imaging under treatment with NB360 or vehicle food pellet for 3 months. Around 24 
hours before imaging, Methoxy-X04 (0.4 to 2.4 mg/Kg body weight, Xcessbio, San 
Diego, CA, USA) was intraperitoneally injected to stain in vivo amyloid plaques 
(Klunk et al., 2002.). Mice were anesthetized by isoflurane supply during each in vivo 
imaging session. Two-photon excitation of Methoxy-X04 labelled Aβ plaques was 
performed at 750 nm and the signal was detected using a short pass (SP) 485 nm 
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filter. Two-photon excitation of eGFP-expressing neuronal structures was performed 
at 880 nm and the signal was detected using a bandpass (BP) 500-550 nm filter. To 
exclude autofluorescent spots from analysis, we also recorded emission signals at 
590-650 nm. These auto-fluorescent spots were found in the neuropil and within 
neuronal and glial cells. A x20 1.0 NA water-immersion objective (Zeiss) was used. 
Overview images of eGFP expressing neuronal structures were taken at low 
resolution (logical size 512 × 512 pixels; physical size x, y, z: 424.3 x 424.3 x 300 
µm; z-step = 3 µm) up to a depth of 300 µm to find the same position over time. 
Overview images of amyloid plaques were taken at high resolution (1300 x 1300 
pixels; physical size x, y, z: 424.77 x 424.77 x 200.00 µm). At least 2-3 overviews 
were taken per animal at each imaging session. High-resolution images (logical size 
512 × 512 pixels; physical size x, y, z: 84.9 x 84.9 x 40-60 µm; z-step = 1 µm) of 
single Aβ plaques and eGFP-expressing axons/neurites surrounding them were 
taken for further analysis. Dystrophic axons were 3D reconstructed over time.   
 
5. Immunohistochemistry and confocal imaging 
 
At the end of the long-term 2-photon imaging, mice were anaesthetized with an 
intraperitoneal injection of a solution of ketamine/xylazine (0.14 mg / g body weight; 
WDT / Bayer Health Care) and transcardially perfused with phosphate buffered 
saline (PBS) followed by 4% paraformaldehyde in 0.12 M sodium phosphate buffer 
(PB), pH: 7.4. The brain was then removed and post-fixed for 24 h at 4°C in the 
same fixative. To obtain coronal sections, the brain was washed in 0.1 M PB and 
sections of 50 µm were cut with a vibratome (Leica VT 1000S). The study was 
focused on the supragranular neocortical layers between bregma −1.64 and −2.12 
mm, with the aim of analyzing similar layers and cortical areas as in the in vivo study. 
In addition, six 10 months-old mice which were not used for in vivo imaging 
experiments were kept under treatment (NB360 or vehicle food pellets) as described 
before.      
Immunohistochemistry was performed on free-floating sections to perform a 
quantitative analysis of the presence of different markers in eGFP-expressing 
dystrophic axons. Samples were permeabilized (2% Triton-PBS) overnight at room 
temperature. Sections were blocked (10% normal goat serum-PBS for 2h at room 
temperature, followed by incubation with primary antibody (diluted in 3% normal goat 
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serum, 0.3% Triton-X100, 0.05% sodium azide – PBS) for 2 overnights at 4°C. 
Sections were washed in 3% normal goat serum, 0.3% Triton-X100, 0.05% sodium 
azide – PBS (3x10 min) and then labeled with fluorescently labeled secondary 
antibodies, diluted in the same buffer as for first antibodies, overnight at 4°C. 
Sections were washed again (3x10 min). Fibrillar Aβ plaques were stained with 
Methoxy-X04 (0.01 mg/ml in 0.1 M PB) for 20 min at room temperature and washed 
(3x10 min). Sections were then mounted on microscope slides using Fluorescent 
Mounting Medium (Dako, Glostrup, Denmark). 
Antibody information (including commercial sources and dilutions) can be found in 
Table 1.  
 
Table 1: List of antibodies used for immunostainings.  
Antibody Source Catalog/clone no. Dilution 
LAMP1 Abcam  ab25245 1:500 
BACE1 Cell Signaling  5606S 1:200 
Aβ42 Millipore ABN 13 1:400 
Aβ4G8 BioLegend SIG-39220 1:500 
 
To analyze normal and dystrophic axons around Aβ plaques, 16-bit-images (logical 
size 2048 x 2048 pixels; physical size x, y, z: 212.44 x 212.44 x 29.50 µm and logical 
size 1024 x 1024 pixels; physical size x, y, z: 106.17 x 106.17 x 20.80 µm) were 
acquired with a LSM 780 confocal microscope (Zeiss) equipped with a laser and with 
the objective Plan Apochromat 40x 1.4 Oil DIC M27. For analysis of the number of 
plaques containing dystrophic and normal axons after both NB360 and vehicle 
treatment, fluorescence images of somatosensory cortex were acquired through the 
20x objective (Zeiss Plan-NEOFLURAR) in frames, using Apotome 2 microscope 
(Carl Zeiss).   
 
6. Aβ quantification  
 
Forebrains from APPSwe/PSEN1dE9 x GFP-M mice were isolated at the end of 
treatment period, frozen and homogenized in 9 volumes of ice-cold Tris-buffered 
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saline (pH 7.4) containing Complete protease inhibitor cocktail (Roche Diagnostics, 
Penzberg, Germany) using a Sonifier 450 (Branson) and stored in aliquots at -80 °C. 
Triton X-100 soluble Aβ was extracted by mixing 50 µl 2 % Triton X-100 with 50 µl 
homogenate, incubated for 15 min on ice and subsequently vortexed, followed by 
ultracentrifugation at 100.000xg for 15 min. The clear supernatant was diluted to a 
final forebrain dilution of 1:100 and used for analysis. For the extraction of insoluble 
amyloid peptides, 50 µl forebrain homogenate was mixed with 117µl of 100 % formic 
acid and stored on ice for 15 min with vortexing. Samples were neutralized with 950 
µl 1 M Tris base, containing Complete protease inhibitor cocktail (Roche, Basle, 
Switzerland) and stored overnight at room temperature. After 15 min centrifugation at 
14000 rpm the supernatant was used for analysis.  
Aβ40 and 42 were determined using the electrochemiluminescence immuno assay 
kits from Meso Scale Discovery (Rockville, MD, USA) in either singlet or triplex 
format. Samples and standards were prepared according to the manufactures 
protocols. The kit based on 6E10 was used for CSF or plasma samples and 
APPSwe/PSEN1dE9 x GFP-M brain. Soluble APPα and sAPPβ from mice brains 
were determined from the 100.000xg supernatant and analyzed with Meso Scale 
Discovery commercial kits. C-terminal fragments C83 and C99 were determined 
from Western blots. Forebrain homogenates dephosphorylated with lambda protein 
phosphatase and run on a 10 % Tris-bicine gel with 8 M urea. After transfer to 
Immobilon P membranes (Bio-Rad Bedford MA USA), bands were probed with APP 
C8 antibody (recognizing the C-terminus of APP) and detected with goat anti-mouse 
IgG Fab fragment AlexaFluor680 (Invitrogen). The same gel was used to visualize 
Aβ1-40 and 1-42 using the N-terminal antibody beta1 and goat anti rabbit IgG IRdye 
800CW (Odyssey). Full-length human APP was detected using an in house immune 
assay based on the MSDECL system.  
 
7. Electron microscopy preparation and TEM imaging 
 
Three APPSwe/PSEN1dE9 mice vehicle-treated and three APPSwe/PSEN1dE9 
mice NB360-treated were transcardially perfused with 4% paraformaldehyde in 0.12 
M PB, pH 7.4. Plastic-embedded sections were studied by correlative light and 
electron microscopy, as described in detail elsewhere (J. DeFelipe and Fairén 1993).  
Briefly, sections were photographed under the light microscope and then serially cut 
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into semithin (2-µm thick) sections on a Leica ultramicrotome (EM UC6, Leica 
Microsystems). The semithin sections were stained with 1% toluidine blue in 1% 
borax, examined under the light microscope, and then photographed to locate Abeta 
plaque regions of interest. Serial ultrathin sections (50- to 70-nm thick) were 
obtained from selected semithin sections on a Leica ultramicrotome, and collected 
on formvar-coated single-slot nickel grids and stained with uranyl acetate and lead 
citrate. Digital images were captured at different magnifications on a Jeol JEM-1011 
TEM (JEOL Inc., MA, USA) equipped with an 11 Megapixel Gatan Orius CCD digital 
camera. 
 
8. Images, data processing and statistics 
 
Deconvoluted 2-photon images (AutoQuantX2, Media Cybernetics) were processed 
by Imaris software (Bitplane AG, Zurich, Switzerland) to obtain the 3D 
reconstructions of the dystrophic axons and Aβ plaques for analysis of the volumes 
of each of them at the different time points. Plaque volumes were extracted by 3D-
surface-rendering with background subtraction and a threshold of 500. 
Dystrophic axons were manually segmented in the image stacks. Only dystrophic 
and parent axons that were present in the whole imaging stack in all time points 
were reconstructed. An axonal segment was considered dystrophic when its volume 
doubled the volume of the non-dystrophic axonal segment.    
In order to better show the details of the dystrophic axons, the representative images 
were processed using the burn tool in Adobe Photoshop CS6 to reduce the 
autofluorescence.   
Data are represented as mean±SD unless specified otherwise. Data were analyzed 
by using GraphPad Prism 5.04 software (GraphPad Inc., La Jolla, CA, USA) using 
the indicated statistical tests. 	
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RESULTS 
 
 
1. Reduction of Aβ40 and Aβ42 levels by pharmacological inhibition of BACE1 
 
The novel BACE1 inhibitor NB360 (Figure 11) can be administrated orally (food 
pellet dosing, 0.25 g/kg). It crosses effectively the BBB and has been shown to 
decrease the progression of Aβ deposition in the brains of APP transgenic mice as 
well as a reduction of Aβ40 and Aβ42 levels in different species like rats, dogs and 
mice (Neumann et al. 2015). We verified these findings in our mouse model, in which 
treatment for 15 days with NB360 caused a significant decrease in Aβ40 and Aβ42 
levels in cerebral cortex and plasma (Figure 12). Vehicle-treated mice did not show 
significant changes of Aβ40 and Aβ42 levels either in cortex or plasma (Figure 12).  
 
	
 
Figure 12:  Pharmacological inhibition of BACE1 potently reduces Aβ40 and Aβ42 levels.  The 
Aβ40 and Aβ42 levels are reduced in mouse cortex (A, B) and the Aβ40 levels are reduced in plasma 
(C) by NB360 after 15 days of administration through food pellets. Data presented as mean ± 
SEM, n = 4 per group; t-test. *p < 0.05; **p < 0.01; ***p < 0.001.  
 
 
 
 
2. Inhibition of BACE1 induces hair depigmentation  
 
A recent publication on long-term effects of BACE1 inhibitor on hair depigmentation 
showed that chronic dual exposure to the equipotent BACE1/BACE2 inhibitor 
(NB360) displayed a dose- and exposure- dependent and irreversible hair 
depigmentation due to the inhibition of BACE2 which blocks PMEL17 processing and 
reduces melanin production (Shimshek et al. 2016). Indeed, in our study, 2-3 weeks 
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after initialization of BACE1 inhibitor treatment mice showed hair depigmentation. In 
some animals the hair depigmentation was on the ventral part and later was spread 
both on ventral body and dorsal part with an irregular pattern (Figure 13). Vehicle-
treated mice did not show any hair color changes. 
 
Figure 13: BACE1 inhibition induces hair depigmentation in mice. (A) Example photo of vehicle-
treated mouse. (B) Upon chronic treatment with NB360 mice developed grey patches (black arrows) 
on their fur. Scale bar 20 mm. 
 
3. BACE1 inhibitor rescues the dynamics of axonal dystrophies  
	
Several approaches to target Aβ production via inhibition of γ-secretase or antibody 
therapy have not yet resulted in considerable clinical benefits. Besides, the 
persistent challenging concept of designing BACE1 inhibitors, which can efficiently 
penetrate the brain and decrease Aβ levels, has proven their potential therapeutic 
approach for limiting plaque-associated presynaptic pathogenesis. However, due to 
some failures with clinical trials of BACE1 inhibitors, new compounds are currently 
under studies to test their proper efficacy and safety profiles (Lucas, Fukushima, and 
Nozaki 2012; May et al. 2011; H. Wang, Li, and Shen 2013; Yuan et al. 2013; 
Riqiang Yan and Vassar 2014; Robert Vassar and Kandalepas 2011).  
To study possible benefits of long-term BACE1 inhibition on the dynamics of plaque-
associated axonal dystrophies, we performed chronic in vivo 2-photon imaging in the 
somatosensory cortex of adult APPSwe/PSEN1dE9 x GFP-M mice. One month after 
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the implantation of the cranial window, we identified in the supragranular layers of 
the somatosensory cortex axonal dystrophies, which were visible close to Aβ 
plaques (Figure 14). The imaging started when mice were 6 months-old (initial stage 
of amyloid pathology) and was prolonged until the age of 10 months-old (advanced 
stage of the disease). 
 
	
	
Figure 14: Dystrophic axons in the supragranular layers of the somatosensory cortex and 
long-term in vivo imaging of APPSwe/PSEN1dE9 x GFP-M mice. (A) Schematic representation of 
the cranial window implanted over the somatosensory cortex. (B) Overview and detailed projection of 
the selected imaging area. (C) Experimental timeline: 4 weeks after window implantation (month zero) 
imaging was performed over four months, once every week (black arrowheads) and after the first 
month of imaging, animals were treated with BACE1 inhibitor or vehicle. Scale bar 20 µm. 
 
 
The individual study of the axons and their dystrophies was achievable due to the 
crossing between our AD model and the GFP-M model, which displays a low density 
of neurons expressing eGFP. 
The dynamics of axonal dystrophies were monitored before and during the treatment 
with NB360 (Neumann et al. 2015) (food pellet dosing 0.25g/kg body weight; over 
three months) and compared with vehicle-treated animals (Figure 15A-C). 
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Using the Imaris software, all observed dystrophic axons were 3D reconstructed 
(Figure 15 – lower panels of each representative image) and the volume of each 
dystrophy was measured in order to study their variation over time.   
Interestingly, three weeks after treatment with BACE1 inhibitor, the volume of the 
axonal dystrophies decreased significantly (Figure 16B). During the treatment, we 
observed a gradual and notably reduction of the volume in the majority of detected 
dystrophies (Figure 16B and C), an effect that was paralleled with the absence of 
development of new dystrophies. In vehicle-treated mice, we observed a dynamic 
variability in the volume of the axonal dystrophies over time (Figure 16A and C).  
Overall, our data demonstrate a significant effect of BACE1 inhibitor on the 
development of dystrophic axons.	
	 40	
	
	
Figure 15: BACE1 inhibitor recovers dystrophic axons. (A-C) Maximum projection of the 
representative images of GFP-label dystrophic axons taken in vivo by 2-photon microscopy before 
and after NB360 and vehicle treatment. The arrowheads indicate the dystrophic axon and its 
corresponding 3D reconstruction in the lower panel. Grey color of the axon reconstruction indicates 
axon recovered (normal axon) by BACE1 inhibition. Scale bar 10 µm. 
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Figure 16: Size dynamics of axonal dystrophies. Changes in the volume of the different axonal 
dystrophies observed over time during NB360 (A) and vehicle (B) treatment. (C) Mean volume of 
axonal dystrophies during NB360 and vehicle treatment. Data presented as mean ± SEM, n = 5 
(NB360 group) and n= 3 (vehicle group); two-way ANOVA with Bonferroni post-test. *p < 0.05; **p < 
0.01; ***p < 0.001.  
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4. BACE1 inhibitor affects Aβ plaque growth in cerebral cortex 
	
Aβ plaque formation and growth are major hallmarks of AD pathology and appear to 
be closely associated with dystrophic neurites and synaptotoxic effects (Fiala 2007; 
Gouras, Almeida, and Takahashi 2005; Arendt 2005; Scheibel and Tomiyasu 1978). 
Therapeutic interventions aimed to reduce the production of extracellular Aβ. Based 
on the constant generation of Aβ from the proteolytic processing of APP mainly by 
BACE1, the use of BACE1 inhibitors has been emerged as a potential approach for 
limiting Aβ-mediated presynaptic dysfunctions (Riqiang Yan et al. 2016).  
The APPSwe/PSEN1dE9 mice begin to develop Aβ plaques in the cortex by 6 
months of age (Jankowsky et al. 2004) which continue growing in a size-dependent 
manner up to around 12 months old (Monica Garcia-Alloza, Robbins, et al. 2006).   
In order to study the presence of Aβ plaques and the associated formation of axonal 
dystrophies, by long-term two-photon in vivo imaging we followed individual plaque 
growth and formation by measuring the volume over 4 months. Prior to the 
treatment, we monitored the plaque growth rate, which is considered as the baseline 
for both NB360 and vehicle-treated mice.  
 
 
 
Figure 17: BACE1 inhibitor decreases plaque growth rate. (A) Time series of a single plaque as a 
surface-rendered object as derived from 3D image analysis. Scale bar 20 µm. (B) Comparison of the 
plaque growth rates resulting from the volume analysis with the values obtained from the vehicle- and 
NB360-treated mice. Data presented as mean ± SEM, n = 5 (NB360 group) and n= 3 (vehicle group); 
t-test. *p < 0.05; **p < 0.01; ***p < 0.001. 
 
The kinetics of amyloid plaque formation and growth were similar to the published 
studies describing the same or other mouse models (Burgold et al., 2011, 2014; 
Bittner et al., 2012; Jung et al. 2015) (Figure 17). Aβ plaques can be characterized 
into large plaques and small plaques. Independently of the deposit size, the NB360-
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treated mice showed a remarkably decrease in the plaque growth rate compared 
with vehicle-treated mice (Figure 17). In addition, mice treated with BACE1 inhibitor 
exhibited a reduced plaque density compared with vehicle-treated mice (Figure 18) 
and was not observed the formation of new plaques. Although plaque growth rate 
was robustly decreased in NB360-treated mice, shrinkage of plaques was not 
observed. These results agree with complementary findings in the literature 
(Neumann et al. 2015; Luo and Yan 2010; Devi, Tang, and Ohno 2015; Stamford et 
al. 2012; Riqiang Yan et al. 2016). Through pharmacological inhibition of BACE1 by 
NB360, generation of new Aβ peptides is reduced preventing the growth and 
formation of plaques.  
 
 
 
Figure 18: BACE1 inhibition decreases the number of dystrophies associated with amyloid 
plaques. (A-D) Representative images of eGFP-labeled dystrophic axons in the somatosensory 
cortex in vicinity to Aβ plaques stained with Methoxy-X04 (blue) (A-B); Orange circles represent the 
Aβ plaques associated with axonal dystrophies in vehicle- (C) and NB360-treated (D) brain slices. 
Purple circles represent the Aβ plaques without axonal dystrophies. Scale bar 500 µm (E) 
Comparison between the number of plaques and its association with axonal dystrophies after NB360 
treatment. Data presented as mean ± SEM, n = 8 (NB360 group) and n= 6 (vehicle group); two-way 
ANOVA with Bonferroni post-test. *p < 0.05; **p < 0.01; ***p < 0.001.  
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5. Inhibition of BACE1 attenuates the progression of axonal pathology 
depending on the distance between Aβ fibrils and axons  
   
The gradual decrease in the volume of axonal dystrophies during BACE1 inhibitor 
treatment could be monitored in vivo for 3 months. The majority of dystrophic axons 
analyzed were recovered. As chronic in vivo imaging is limited to a certain area of 
the somatosensory cortex, we investigated the distribution of plaque-associated 
axonal dystrophies in somatosensory brain slices of both NB360 and vehicle-treated 
mice. Confocal imaging of axons surrounding amyloid plaques in layer I/II (same 
region of interest as in the in vivo imaging-experiments) was performed in brain 
slices.  
Two remarkable differences between the vehicle- and inhibitor-treated cohorts were 
found. Firstly, although we detected the presence of axonal dystrophies in NB360-
treated mice, the number was notably reduced compared with vehicle-treated mice. 
Secondly, the number of plaque deposits was significantly reduced in comparison to 
vehicle-treated mice (Figure 18). Although these observations are consistent with the 
in vivo microscopy data, it did not determine the temporal relationship between 
reduction of axonal dystrophies and the decreased plaque growth rate during BACE1 
inhibition. To resolve this question, we performed high-resolution confocal imaging in 
brain slices from NB360-treated and vehicle-treated mice that were stained with 
methoxy-X04 and antibodies against BACE1, Aβ (Aβ4G8) and LAMP1. As expected 
the pattern of BACE1 immunostaining was similar in both NB360-treated and 
vehicle-treated brain slices. Our main observation was that Aβ showed dramatic 
changes in staining intensity and localization in NB360-treated mice. Aβ staining was 
strongly reduced in NB360-treated mice and localized at the plaque core when 
compared with vehicle-treated mice (Figure 19). This observation of reduced Aβ 
staining is consistent with the reduced Aβ levels in both forebrain and plasma after 
BACE1 inhibition (Figure 12). 
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Figure 19: Remaining dystrophies are in contact with Aβ fibrils after BACE1 inhibitor 
treatment. Immunofluorescence staining with antibodies against BACE1 and Aβ showed that after 
BACE1 inhibitor treatment, the amount of Aβ is reduced. Scale bar 20 µm. All data in this figure were 
acquired from the cerebral cortices of 10 months old mice.  
 
 
In addition, given that LAMP1 accumulates at amyloid plaques and reside within the 
dystrophic axons (Kandalepas et al. 2013; Gowrishankar et al. 2015; Sadleir et al. 
2016), we investigate the impact of BACE1 inhibitor on the accumulation of 
lysosomal membrane proteins at amyloid plaques through a comprehensive 
immunofluorescent staining analysis of the brain slices of the vehicle and NB360-
treated mice. After analysis of the immunofluorescent staining patterns for LAMP1, 
our major observation was that LAMP1 staining area and localization at amyloid 
plaques was unchanged by BACE1 inhibition compared to vehicle-treated brains 
(Figure 20). Although after BACE1 inhibition both plaque growth rate and plaque 
density are reduced, LAMP1 accumulations are present at all sizes of amyloid 
plaques (Figure 20). This close relationship between LAMP1 accumulations and 
amyloid plaques was uniformly observed in both vehicle and NB360-treated brain 
slices (Figure 20). Visualization of axons via transgenic expression of eGFP showed 
that axonal dystrophies colocalized with LAMP1 in both vehicle and NB360-treated 
mice (Figure 20). Likewise LAMP1 accumulations were always found at amyloid 
plaques where the remaining axonal dystrophies were located. Moreover, axons 
distant from amyloid plaques were morphologically normal (Figure 20). 
In addition, to relate these LAMP1 accumulations to the remaining axonal 
dystrophies, we examined amyloid plaques with dystrophic axons in NB360-treated 
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brain slices. We performed 3D reconstructions of axons surrounding plaques and 
further examined the colocalization of LAMP1 with axonal dystrophies and its 
distance to amyloid plaques. Interestingly, by analyzing the axons via 3D 
reconstructions, we observed that the remaining axonal dystrophies are localized in 
the border and inside plaques (Figure 21) as visualized with Methoxy-X04 staining. 
Likewise, the remaining axonal dystrophies strongly colocalized with LAMP1 signal 
while normal axons were not coenriched with LAMP1 (Figure 21G). Thus, although 
the presence of LAMP1 around plaques has been reported, we demonstrate that 
normal axons surrounding amyloid plaques, which we consider the recovered axons 
after BACE1 inhibition, were in close physical association to plaque fibrils (Figure 19 
and 20). These observations, in addition to complementary findings in the literature 
(Kandalepas et al. 2013; Gowrishankar et al. 2015; Sadleir et al. 2016) revealed that 
pharmacological inhibition of BACE1 is more effective on axonal dystrophies 
localized at the periphery of the plaque which physical contact with amyloid fibrils is 
shorter due to the decreased plaque growth.  
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Figure 20: LAMP1 accumulations are present at all sizes of amyloid plaques after BACE1 
inhibitor. Representative images of staining for LAMP1 at amyloid plaques (stained with Methoxy-
X04) and the surrounding axons in cerebral cortices of vehicle (A) and NB360-treated (B) mice. 
Normal axons are marked by long arrows and dystrophic axons are marked by short arrows. Scale 
bar 20 µm. 
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Figure 21: Dystrophies are localized inside and at the border of the plaque. (A) Amyloid plaque 
stained with Methoxy-X04. (B) eGFP-expressing axons. (C) Superimposed fluorescent image of the 
plaque and associated axons. (D) 3D reconstruction of a normal axon (left) and a dystrophic axon 
(right). (E) Immunofluorescence staining for LAMP1. (F) Superimposed fluorescent image of the 
plaque and LAMP1 staining. (G) LAMP1 intensity in both dystrophic and normal axons. (Lower panel) 
Distance between the dystrophic axons and its co-localization either with LAMP1 and Aβ plaques. 
Circles in dashed red line represent the inside of the plaque, circles in dashed blue line represent the 
border and circles in dashed grey line represent the periphery of the plaque. Scale bar 20 µm. All data 
in this figure were acquired from the cerebral cortices of 10 months old mice. 
 
 
 
6. Ultrastructural analysis of the intracellular accumulation of organelles at 
amyloid plaques 
 
The recovery of dystrophic axons, the reduction in the volume of axonal dystrophies, 
the decreased plaque growth rate and the robust LAMP1 staining within axonal 
dystrophies after BACE1 inhibition, suggested that BACE1 inhibitor is less effective 
on dystrophic axons which dystrophies are localized inside of the plaque. To 
investigate this possibility at a structural level, we examined sections of vehicle and 
NB360-treated mouse brain by electron microscopy (EM). We found dystrophies 
contacting amyloid plaques in both vehicle (Figure 22A) and NB360-treated (Figure 
22B) sections. Accordingly, upon a higher magnification, EM revealed the presence 
of a diversity of putative autophagic vesicles (AVs) within dystrophies that 
immediately surround amyloid plaques in both vehicle (Figure 22C-E) and NB360-
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treated (Figure 22F-H) sections. These AVs have distinct morphologies such as 
heterogeneous electron dense double-membrane vesicles, electron dense 
compacted amorphous vesicles, multilamellar vesicles, translucent vesicles and 
amorphous electron dense vesicles. The most common morphology of AVs present 
in dystrophies is electron dense compact amorphous and multilamellar vesicles. 
Overall, we found a substantial accumulation of AVs within dystrophies surrounding 
amyloid plaque, in both vehicle and NB360-treated sections, indicating that BACE1 
inhibition does not alter the intracellular accumulation of organelles within 
dystrophies that contact the amyloid plaque. 
 
Given that the physical contact of axons with amyloid plaques causes the formation 
of dystrophies, our results suggest that during BACE1 inhibition, the concentration of 
toxic Aβ species and aggregation into insoluble β-sheet amyloid fibrils is diminished, 
decreasing plaque growth. Thus, physical contact between amyloid fibrils and both 
dystrophic and normal axons is reduced. Therefore, the accumulation of BACE1, 
APP and autophagic vesicles as well as axonal swellings decreases. Microtubules 
can support the normal axonal transport of BACE1, vesicles and other organelles 
leading to the recovery of the dystrophic axons and prevention of dystrophies 
formation (Figure 23).  
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Figure 22: Ultrastructural analysis of organelle accumulation surrounding amyloid plaques. (A) 
Electron panoramic micrograph of vehicle-treated cerebral cortex tissue showing a central amyloid 
plaque (marked in red) surrounded by dystrophies. (B) Electron panoramic micrograph of NB360-
treated cerebral cortex tissue showing a central amyloid plaque (marked in red) surrounded by 
dystrophies. (C-E) Higher magnification of the dystrophies from plaque in A reveals the morphology of 
organelles that accumulate within cellular processes that contact the amyloid plaque. (F-H) Higher 
magnification of the dystrophies from plaque in B reveals the morphology of organelles that 
accumulate within cellular processes that contact the amyloid plaque. Arrows point out synaptic 
contacts. Scale bar 8 µm. 
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Figure 23: Working hypothesis. (A) Schematic diagram that summarizes the formation of the axonal 
dystrophies in AD and (B-C) how BACE1 inhibition can recover dystrophic axons associated with 
plaques. (B) Dystrophic axons are localized inside, at the border or at the periphery of the amyloid 
plaque. (C) After BACE1 inhibition, the physical contact between amyloid fibrils and axons localized at 
the periphery is reduced facilitating the recovery of the dystrophic axon.    
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DISCUSSION 
 
BACE1 levels and activity are increased in postmortem brains and CSF from AD 
brains (Fukumoto et al. 2002; Holsinger et al. 2002; Tyler et al. 2002; Yang et al. 
2003; Li et al. 2004; Harada et al. 2006). Accumulation of BACE1 begins to increase 
in parallel with amyloid pathology and is observed predominantly in dystrophic 
presynaptic terminals surrounding amyloid plaques in brains of AD patients and AD 
mouse models (Zhao et al. 2007; Kandalepas et al. 2013). The amyloid cascade 
hypothesis of AD postulates that the overproduction, deposition and/or reduced 
clearance of Aβ peptides in the brain is a key event that triggers the synaptic 
degeneration and ultimately the deterioration of cognitive function and memory (J. 
Hardy and Selkoe 2002; Lacor et al. 2007). Given that BACE1 is the required 
therefore rate-limiting enzyme for Aβ generation and (R. Vassar et al. 1999; Ghosh, 
Brindisi, and Tang 2012), it represents one of the prime targets for the development 
of disease-modifying drugs in AD. Several BACE1 inhibitors are currently in 
advanced phases of clinical trials (Lucas, Fukushima, and Nozaki 2012; May et al. 
2011). However, the development of drugs with a favorable safety profile that 
pharmacologically inhibit BACE1 has a long way to go before they are applicable in 
the treatment of AD (Yuan et al. 2013; Riqiang Yan and Vassar 2014; Riqiang Yan et 
al. 2016; Robert Vassar and Kandalepas 2011).   
In recent years there has been considerable debates regarding how plaques act as a 
neurotoxic agent in AD, and how BACE1 elevation is triggered by amyloid pathology. 
Although much data exist on the accumulation of BACE1 in swollen dystrophic axons 
surrounding plaques and its association with lysosomal dysfunction (Vickers et al. 
1996; Zhao et al. 2007; Zhang et al. 2009; Kandalepas et al. 2013), two recent 
comprehensive studies provided new insights into the fundamental mechanisms of 
presynaptic dystrophy formation driven by extracellular Aβ deposits. Importantly, 
they revealed that the formation of axonal dystrophies is caused by a feed-forward 
mechanism of increased accumulation of BACE1, APP and lysosomes (preferentially 
lysosome precursors). This is a result of a local impairment in the retrograde axonal 
transport triggered by Aβ generation and plaque progression which mediate axonal 
microtubule disruption and microtubule-based transport impairment (Gowrishankar et 
al. 2015; Sadleir et al. 2016).     
Previous studies have reported treatment strategies for the modulation of plaque 
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associated-axonal dystrophies (M. Garcia-Alloza et al. 2007; R. P. Brendza et al. 
2005; T. L. Spires 2005; Tsai et al. 2004; D’Amore et al. 2003). However, these 
studies did not monitor the formation of axonal dystrophies and plaque growth 
kinetics over an observation period of 4 months including a long-term treatment.  
To investigate the pharmacological effect of BACE1 inhibition on the dystrophic 
neurites formation and plaque progression, we combined chronic in vivo two-photon 
imaging and confocal imaging in mice treated with BACE1 inhibitor. Fortunately, 
transgenic mouse models recapitulate some of the pathological aspects of AD 
allowing the analysis of disease initiation and progression. In our study, we observed 
that around 21% of the axons near plaques developed dystrophies. The 3D 
reconstructions of the eGFP-expressing dystrophic axons enabled us to observe that 
dystrophies have different sizes and morphology. Moreover, as shown in vehicle-
treated mice, dystrophies do not grow regularly but they can increase and decrease 
their volume over time (Figure 16A). Furthermore, we show that chronic treatment 
with the novel BACE1 inhibitor, NB360, rescues the majority of plaque-associated 
axonal dystrophies in the brains of APPSwe/PSEN1dE9 x GFP-M mouse models 
(Figure 16B).  
 
Two important conclusions emerge from our study:  
 
1) Reduction of axonal BACE1 activity attenuates the local generation of Aβ in 
the vicinity of the amyloid deposits and thus facilitates the recovery of axonal 
dystrophies and prevents formation of new dystrophies. 
2) Decreasing plaque growth rate prevents the toxic effects derived from Aβ 
generation in the neighboring axons and the formation of new plaques. 
 
Taken together, as illustrated in Figure 23, our results suggest the following 
hypothesis regarding the effect of BACE1 inhibition on axonal dystrophies formation 
and plaque progression. Treatment with BACE1 inhibitor reduces Aβ generation and 
plaque growth. This effect results in a reduced physical contact with the surrounding 
normal and dystrophic axons. Therefore, the decreased neurotoxicity stems from a 
reduction of either soluble Aβ oligomers or insoluble Aβ fibrils, benefitting the 
stabilization of microtubules and promoting the extension of newly polymerized 
microtubules from the distal part of the dystrophy towards the region close to the 
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plaque. Microtubule-based axonal transport is re-established and vesicular cargoes 
proximal and distal to the plaque are transported. Because BACE1 is normally 
degraded by lysosomes, (Koh et al. 2005; Ye and Cai 2014; Kandalepas et al. 2013) 
its transport to lysosomes for degradation is efficient and vesicles containing BACE1 
and APP accumulate less at the axons after treatment. After treatment, BACE1 
levels and turnover through retrograde transport are regulated controlling APP 
processing and Aβ generation in the dystrophic region of the axon. Axonal swellings 
decrease gradually thereby reducing physical contact with Aβ fibrils preventing the 
formation of new axonal dystrophies. Our hypothesis is supported by previous 
studies that detected a partial reduction of the dystrophic neurites surrounding 
plaques using immunotherapy (Lombardo et al. 2003) or antioxidant treatments 
(Monica Garcia-Alloza, Dodwell, et al. 2006; M. Garcia-Alloza et al. 2007). 
Thus, BACE1 inhibition is beneficial in slowing down the progression of dystrophic 
pathology associated with plaque growth, improving functional synaptic transmission 
and cognitive functions.  
 
Why are some dystrophies still present after long treatment with BACE1 
inhibitor? 
 
The spherical and extracellular Aβ plaques are a pathological feature of AD. After 
their formation, they can be morphologically characterized as dense-core plaques 
and diffuse plaques (Fiala 2007).  
Despite the extensive overproduction and deposition of Aβ as the sources of 
neurotoxicity in AD mouse models and in AD, ongoing debates about the steps of 
the amyloid cascade hypothesis have been suggesting mature fibrils as the cause of 
disease pathogenesis. This hypothesis is based on the findings that amyloid plaques 
are associated with neuritic dystrophies and synapse loss (D’Amore et al. 2003; 
Monica Garcia-Alloza, Dodwell, et al. 2006; Lombardo et al. 2003; Urbanc et al. 
2002; Lorenzo and Yankner 1996; Stéphan, Laroche, and Davis 2001; Cohen et al. 
2013).  
Dense-core plaques are defined as fibrillary amyloid deposits with a compact core 
and associated with axonal dystrophies embedded within the dense-core or in the 
vicinity of the plaque (Masliah et al. 1994; Su, Cummings, and Cotman 1998; T. C. 
Dickson and Vickers 2001; Shah et al. 2010). The microenvironment within and 
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around these dense-core plaques is considered toxic compared with diffuse plaques, 
and it is favorable for additional plaque development contributing to the amyloid 
cascade pathology (Selkoe 1991; Urbanc et al. 2002; J. Hardy and Selkoe 2002; 
Bero et al. 2011; Beker et al. 2012; Alberto Serrano-Pozo et al. 2016). 
Although dense-core plaques are defined by the presence of insoluble Aβ fibrils, 
they also display a peripheral halo composed by soluble and toxic oligomeric 
intermediates (Shankar et al. 2008; Koffie et al. 2009; Hong et al. 2011; Koffie et al. 
2012).     
Therefore, preventing the production and limiting the aggregation of Aβ through 
inhibition of BACE1 may prevent or limit the progression of the pathology associated 
with plaque growth. 
In the present work we were able to monitor the effect of chronic BACE1 inhibition on 
plaque density and plaque growth kinetics over time in a mouse model of AD. In 
agreement with (Neumann et al. 2015), we observed that inhibition of BACE1 by 
NB360 reduced the generation of Aβ peptides (Figure 12) and plaque growth rate 
(Figure 17). However, we did not observe a reduction of the size of the existing 
plaques. These data support the idea that BACE1 inhibition limits the production of 
new Aβ and therefore reduces the density of new-formed plaques, while the effect 
on plaque regression is limited.   
As already mentioned, plaques are considered to be responsible for the abnormal 
swellings of the surrounding neurites (Knowles et al. 1999; D’Amore et al. 2003; 
Monica Garcia-Alloza, Dodwell, et al. 2006). Considering this, we extended our in 
vivo observations and assessed the effect of BACE1 inhibition on axonal dystrophies 
ex vivo using high-resolution confocal imaging. This approach allowed us to explore, 
in more detail, plaques and surrounding axons, which were not possible to observe 
due the limited area of the in vivo imaging. In agreement with our in vivo imaging 
experiments, we observed the presence of axonal dystrophies after the long-term 
treatment with BACE1 inhibitor (Figure 18 and 19). Moreover, these remaining 
dystrophies were located within the dense-core of the plaque and co-localized 
extensively with LAMP1 (Figure 20 and 21).  
Previous EM analysis indicated that the axonal dystrophies are heterogeneous 
containing electron dense and multilamellar vesicles that may be 
autophagic/lysosomal intermediates (Kandalepas et al. 2013; Gowrishankar et al. 
2015). Although our observation at amyloid plaques from vehicle and NB360-treated 
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sections did not show visual differences in the content of organelles within 
dystrophies (Figure 22C-H), it supports our hypothesis regarding the reduced effect 
of BACE1 inhibitor on dystrophies that contact amyloid plaques. Further studies are 
needed to better characterize the heterogeneity of dystrophies after BACE1 
inhibition, and determine its causes and consequences. Besides, further studies in 
order to characterize the type of axon and its susceptibility to recover after BACE1 
inhibitor will further elucidate the mechanisms whereby BACE1 inhibition recovers 
dystrophic axons. 
Taken together, our in vivo and ex vivo results suggest that pharmacological 
inhibition of BACE1 is more effective in the periphery the plaques through reduction 
of the Aβ generation and fibrillization, thus diminishing the propensity to form 
dystrophies. However, has less effect on axonal dystrophies located within the 
dense-core of the plaques, even with reduced Aβ production. This demonstrated that 
the microenvironment within the core of the plaques remains toxic becoming more 
difficult to recover the existing pathology there.  
Our data suggest that pharmacological inhibition of BACE1 limits the generation of 
Aβ and thus reduces plaque growth. Accordingly, diminishing the formation of 
neurotoxic fibrils prevents the progression of presynaptic dystrophic neurites 
surrounding plaques. 
 
 
BACE1 inhibition in mouse models of AD – medical relevance 
 
BACE1 inhibitors are designed to target one of the key drivers of AD progression. 
Although this study was conducted in mice, it shows promise for AD treatment. 
Abnormal accumulation of both BACE1 and APP in dystrophic axons that surround 
amyloid plaques (Zhao et al. 2007; Zhang et al. 2009; Kandalepas et al. 2013), 
suggest that peri-plaque Aβ production accelerate amyloid deposition and induce a 
vicious pathogenic cycle (Torres et al. 2012; Sadleir et al. 2016). Therefore, 
decreasing BACE1 activity in peri-plaque dystrophic axons represents a potentially 
efficacious therapeutic goal of BACE1 inhibition. As shown by the present study, 
BACE1 inhibition in an AD mouse model decreased the Aβ production and 
significantly reduced the plaque growth. As a result, the formation of new amyloid 
plaques was prevented and plaque-associated dystrophic axons have recovered.    
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Despite the challenges of BACE1 inhibitor drug development over the last years, in 
particular the level of BACE1 inhibition, the introduction of several BACE1 inhibitors 
into clinical trials promise a therapeutic approach for AD. Currently, some BACE1 
inhibitors are in phases 1, 2 and 2/3 (Riqiang Yan and Vassar 2014), although two 
BACE1 inhibitors have been terminated due to their toxicity.  
However, important questions concerning therapeutic goals and outcomes remain to 
be answered for future clinical development of BACE1 inhibitors for AD. Given that 
Aβ deposition starts years before the clinical diagnosis of AD and cause the 
formation of axonal dystrophies surrounding amyloid plaques, it raises the questions 
at what stage of AD should be administered the BACE1 inhibitor and how is the 
optimal efficacy of treatment. At this time, this study using the new BACE1 inhibitor 
(NB360) added new insights into the relationship between BACE1 inhibition, Aβ 
reduction, plaque load and axonal pathology associated with plaques, in order to 
estimate the levels of BACE1 inhibition need at a given stage of AD for clinical 
development.     
In this study is shown for the first time that treatment with a BACE1 inhibitor reduced 
the axonal pathology associated with plaques. The NB360 (Neumann et al. 2015) 
used in this study, is not yet developed for clinical trial, but taking into account the 
results of our study raise hopes for future clinical development of BACE1 inhibitors 
for AD.  
 
Although BACE1 inhibitors still have a long way to go before they are applicable in 
the battle against AD, they can at least be used to prevent and slow the progression 
of the disease. 
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